Venbio Select
SlowingFiled to raiseNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed 2026
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Avoro Ventures Fund IIFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
| venBio Global Strategic Fund IV | April 2021 | $550M | $550M | 147 |
| Avoro Ventures Fund | February 2021 | Indefinite | $178M | 46 |
| venBio Global Strategic Fund III | June 2018 | $386M | $386M | 100 |
| venBio Global Strategic Fund II |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kurt von EmsterNot on the current fund | Slowing | Biotech & pharma | 8 |
Classified sectors of Venbio Select’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Venbio Select’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Venbio Global Strategic | 16 | Alexo Therapeutics, Apellis Pharmaceuticals, Attralus, Axonis Therapeutics, Cerus Endovascular, Checkmate Pharmaceuticals, FOG PHARMACEUTICALS, INSAMO, LIMERICK BIOPHARMA, Metacrine, Mirna Therapeutics, NFlection Therapeutics, PRECISION BIOSCIENCES, Solstice Biologics, Tallac Therapeutics, TP Therapeutics |
| Longitude 103.8 East | 3 | Orbus Therapeutics, SutroVax, Vera Therapeutics |
| Longitude Capital | 3 | Orbus Therapeutics, SutroVax, Vera Therapeutics |
| March 2015 |
| $337M |
| $337M |
| 31 |
| Avoro Life Sciences Offshore Fund | July 2010 | Indefinite | $2.2B | 290 |
| Avoro Life Sciences Fund | July 2010 | Indefinite | $3.5B | 292 |
| 1 |
| Behzad AghazadehNot on the current fund | Quiet | Biotech & pharma | 2 | 0 |
| Corey Goodman | Quiet | Biotech & pharma | 11 | 0 |
| Paul BrookeNot on the current fund | Quiet | None listed | 1 | 0 |
| Robert Adelman | Quiet | Biotech & pharma | 5 | 0 |
| Scott EpsteinNot on the current fund | Quiet | None listed | 1 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Longitude Prime | 3 | Orbus Therapeutics, SutroVax, Vera Therapeutics |
| Sofinnova Venture Partners | 3 | Apellis Pharmaceuticals, Checkmate Pharmaceuticals, Vera Therapeutics |
| Caduceus Capital | 2 | Scribe Therapeutics, TP Therapeutics |
| Orbimed Asia Partners | 2 | Scribe Therapeutics, TP Therapeutics |
| Orbimed Genesis | 2 | Scribe Therapeutics, TP Therapeutics |
| ARCH Venture Partners | 1 | Metacrine |
| Lightstone Singapore | 1 | Tallac Therapeutics |
| Lightstone Ventures | 1 | Tallac Therapeutics |
| Polaris Partners | 1 | Metacrine |
| Prince Street | 1 | Orbus Therapeutics |
| Transformation Capital | 1 | FOG PHARMACEUTICALS |
| Versant Venture Capital | 1 | CRISPR Therapeutics AG |
A shared board seat: a company where filings name a Venbio Select partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.